PR Newswire 8/27/2013 — Market News
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that Gilotrif (afatinib) tablets for oral use will be commercially available in the US the week of September 2.
FDA approved Gilotrif on 12 July 2013 as a new first-line — or initial — treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Safety and efficacy of Gilotrif have not been established in patients whose tumours have other EGFR mutations.
Supporting Patient Access to Gilotrif
Boehringer Ingelheim has established a comprehensive patient support programme that will provide a broad range of access and clinical support solutions, including financial support services. One of the goals of this programme, called Solutions Plus, is to help patients who are prescribed Gilotrif gain access to the medicine quickly and affordably.
Until Gilotrif becomes commercially available, eligible patients in need of afatinib may be enrolled in the Expanded Access Program (EAP); at the time of availability, Boehringer Ingelheim will provide support to healthcare professionals and patients to ensure a smooth transition.